All In Biotech

Drug Trial Radar · NCT03785587

A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis

A Multi-Center Open-Label Extension Study to Assess the Long-Term Safety Tolerability and Pharmacokinetics of Sofpironium Bromide Gel 15% Applied Topically to Children and Adolescents Age 9-17 Years Previously Enrolled in BBI-4000-CL-105

Last checked: Nov 20, 2026Latest source record: Mar 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

21

Actual

Start

Dec 21, 2018

Primary completion

Sep 6, 2019

Study completion Sep 6, 2019

Sponsor

Lead sponsor
Botanix PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Dec 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis. This Phase 2 study will assess the long-term safety, tolerability, pharmacokinetics and efficacy of sofpironium bromide gel applied topically to pediatric subjects with axillary hyperhidrosis.

Conditions

  • Primary Axillary Hyperhidrosis

Interventions

  • Sofpironium Bromide Gel, 15%Drug

    Sofpironium Bromide Gel, 15%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Participants With Treatment Emergent Adverse Events (All TEAEs).Time frame: Through study completion (24 weeks).
  2. The Number of Participants With Dermal Tolerability Symptoms of Burning, Stinging, Itching, Scaling or Erythema to the Axillae.Time frame: Through study completion (24 weeks).
  3. The Systemic Exposure (Ctrough) of Sofpironium and Its Primary Metabolite (BBI-4010)Time frame: Through study completion (24 weeks).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northwest Arkansas Clinical Trials Center

    Rogers, Arkansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.